Collegium Pharmaceutical Inc (COLL) Earns “Buy” Rating from Needham & Company LLC

Collegium Pharmaceutical Inc (COLL) Earns “Buy” Rating from Needham & Company LLC

Several other equities research analysts have also recently commented on COLL. Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, March 14th. Jefferies Group LLC set a $24.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a report on Saturday, March 25th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $22.40.

Collegium Pharmaceutical Inc (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Wednesday. They presently have a $25.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 200.48% from the stock’s current price.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.19. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.55 million.

In other news, insider Paul Brannelly purchased 10,000 shares of the stock in a transaction dated Friday, May 12th. The stock was acquired at an average cost of $9.18 per share, for a total transaction of $91,800.00. Following the completion of the transaction, the insider now directly owns 110,227 shares in the company, valued at approximately $1,011,883.86. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 37.93% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NBW Capital LLC raised its position in Collegium Pharmaceutical by 1.8% in the first quarter. NBW Capital LLC now owns 62,030 shares of the specialty pharmaceutical company’s stock worth $624,000 after buying an additional 1,114 shares during the period. Credit Suisse AG raised its position in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the period. Nationwide Fund Advisors raised its position in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the period. American International Group Inc. raised its position in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the period. Institutional investors and hedge funds own 56.60% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:COLL”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment